Business
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial
About this update from Exagen Inc.
CARLSBAD, Calif. , Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025 , before the market opens on Tuesday, March 10, 2026 . John Aballi , President and Chief Executive Officer, and Jeff Black , Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET ( 5:30 a.m. PT ). Conference Call & Webcast: U.S. dial-in: 877-407-0890 International dial-in: +1 201-389-0918 Webcast: Available via the Exagen investor relations website at investors.exagen.com Replay: A telephone replay will be available until Tuesday, March 24, 2026 : U.S. replay: 877-660-6853 International replay: +1 201-612-7415 Replay passcode: 13757484 Webcast: A recording of the webcast will be available one hour after the call concludes via the Exagen investor relations website at investors.exagen.com About Exagen Inc. Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California , Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow Exagen on LinkedIn . Contact: Tina Jacobsen Exagen Inc. [email protected] Source: Exagen Inc.